The subcutaneous implantable cardioverter and defibrillator: Advantages, limitations and future directions

Nishant Verma, John Rhyner, Bradley P. Knight*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The totally subcutaneous implantable cardioverter and defibrillator (S-ICD) represents the most innovative development in implantable cardioverter and defibrillator therapy in the last 15 years. Its development arose out of concern for the long-term complications of transvenous devices. Clinical trials have shown that it is a safe and effective device for patients at risk of sudden cardiac death. The lack of transvenous and intracardiac components makes it an attractive choice for young patients, those with limited vascular access and increased infectious risk. Despite these advantages, the current S-ICD system has limitations, including the inability to deliver cardiac pacing. Future programming and technologic advancements have the opportunity to dramatically improve the efficacy and broaden the patient population treated with the S-ICD.

Original languageEnglish (US)
Pages (from-to)989-999
Number of pages11
JournalExpert review of cardiovascular therapy
Volume13
Issue number9
DOIs
StatePublished - Sep 2 2015

Keywords

  • cardiac arrest
  • subcutaneous implantable cardioverter and defibrillator
  • sudden cardiac death
  • transvenous implantable cardioverter and defibrillator

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The subcutaneous implantable cardioverter and defibrillator: Advantages, limitations and future directions'. Together they form a unique fingerprint.

Cite this